PBH at a glance
Prestige Consumer Healthcare Inc. (PBH, SEC CIK 1295947) filed its latest 10-K annual report on May 14, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), Prestige Consumer Healthcare Inc. (PBH) reported revenue of $1.1 billion (down 4.3% from FY2025) and net income of $190.3 million. Diluted EPS was $3.91.
- As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Prestige Consumer Healthcare Inc. (PBH) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Zerillo Jeffrey on May 11, 2026 of 351 shares at $52.28 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $1.1B
- −4.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 33 funds
- $1.2B · −2 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $336.3M, up 22.7% YoY from $274.1M, driven by OTC Wellness acquisition
- Gross margin 51.3% vs 55.3% YoY, pressured by Pillar5 costs and acquisition inventory step-ups
- Best category Wellness, Sleep & Other, $37.2M North America revenue, up 507.2% YoY
- International OTC strongest segment, revenue $64.5M, up 48.7% YoY
- Cash $46.5M, down $17.4M; operating cash flow $108.7M, down $27.8M YoY; acquisitions used $1.2B in investing cash
Risk Factors
- No material changes to 10-K risk factors during the quarter
- Quarterly results and revenues may fluctuate, limiting comparability across periods
- Future results below analyst or investor expectations could depress securities prices
- Unknown or currently immaterial risks could materially harm business, financial condition, or results
AI summary of the PBH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Earnings announcement covers fiscal quarter and six months ended September 30, 2026
- Results press release attached as Exhibit 99.1, providing the substantive financial details
Item 7.01: Regulation FD Disclosure
- Investor presentations began November 5, 2026, covering results for the quarter and six months ended September 30, 2026
- Exhibit 99.2 contains management’s financial-results slides, the primary source for detailed metrics and outlook
Item EX-99.1: Item EX-99.1
- Q2 revenue $336.3M, up 22.7%, but organic revenue declined 1.6% excluding $65.1M from acquisitions
- Adjusted diluted EPS $1.13, up from $1.07, while GAAP diluted EPS fell to $0.53 from $0.86
Item EX-99.2: Item EX-99.2
- Q2 revenue $336.3M, up 22.7%, but organic revenue declined 1.6% due to sales timing
- Adjusted EBITDA $113.0M, up 30.1%, with margin expanding to 33.6% from 31.7%
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jeffrey Zerillo retiring as Senior Vice President, Operations effective August 14, 2026
- Departure includes all other positions Zerillo holds with Prestige Consumer Healthcare
Item EX-99.1: Item EX-99.1
- Q1 FY2027 revenue $265.7M, up 6.5%, with organic growth 3.2% exceeding expectations
- Adjusted EPS $0.98 versus $0.95, while GAAP EPS fell to $0.61 amid acquisition and facility-remediation costs
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q1 2026 results cover the quarter ended June 30, 2026
- Earnings press release issued August 6, 2026
Item 7.01: Regulation FD Disclosure
- Investor presentations began August 6, 2026, covering results for the quarter ended June 30, 2026
- Exhibit 99.2 contains management’s investor slides, providing the primary financial and strategic details
Item EX-99.2: Item EX-99.2
- Q1 revenue $265.7M, up 6.5%, with organic growth 3.2%, signaling resilient demand despite Clear Eyes supply variability
- Adjusted EPS $0.98 versus $0.95, while adjusted EBITDA $84.1M and margin 31.6%, supporting earnings stability
AI summaries of PBH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PBH
Don't miss the next PBH filing
- Alerts as it files. A push when PBH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PBH, by share count.
- Ask anything. An AI agent that reads every PBH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Clark Celeste A. | A | Aug 4, 2026 | 2,981 | - |
| BYOM JOHN E | A | Aug 4, 2026 | 2,981 | - |
| DArecca James | A | Aug 4, 2026 | 2,981 | - |
| Kelly John F. | A | Aug 4, 2026 | 2,981 | - |
| ZIER DAWN M. | A | Aug 4, 2026 | 2,981 | - |
| Zerillo Jeffrey | Sell | May 11, 2026 | 351 | $52.28 |
| Lombardi Ronald M. | F | May 7, 2026 | 2,543 | $54.59 |
| Sacco Christine | F | May 7, 2026 | 991 | $54.59 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.1B | $1.1B |
| Gross Profit | - | $634.5M | $595.6M |
| Operating Income | - | $336.8M | $309.4M |
| Net Income | - | $214.6M | $190.3M |
| Gross Margin | - | 55.8% | 54.7% |
| Op. Margin | - | 29.6% | 28.4% |
| Net Margin | - | 18.9% | 17.5% |
| Balance Sheet | |||
| Total Assets | $3.3B | $3.4B | $3.5B |
| Equity | - | $1.8B | $1.9B |
| ROE | - | 11.7% | 10.1% |
| Per Share | |||
| EPS | - | $4.29 | $3.91 |
| Cash Flow | |||
| Operating CF | - | $251.5M | $257.6M |
| CapEx | $9.6M | $8.2M | $11.2M |
Source: XBRL data in Prestige Consumer Healthcare Inc. (PBH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PBH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 33 | $1.18B |
| Q2 2026 | 35 | $1.21B |
| Q1 2026 | 34 | $1.50B |
| Q4 2025 | 30 | $1.60B |
| Q3 2025 | 32 | $1.71B |
| Q2 2025 | 32 | $2.24B |
| Q1 2025 | 31 | $1.65B |
| Q4 2024 | 27 | $1.27B |
- Citadel Advisors LLC+264.0K (+47%)
- Millennium Management+153.1K (+330%)
- Invesco Ltd+135.2K (+33%)
- Franklin Resources+96.8K (+869%)
- State Street Corp+94.5K (+4%)
- WESTWOOD HOLDINGS GROUP INC−116.3K (-16%)
- D.E. Shaw & Co−107.1K (-34%)
- Goldman Sachs Group−86.5K (-15%)
- T. Rowe Price Group−86.3K (-25%)
- Citigroup−60.6K (-42%)
- FMR LLC (Fidelity)−210.5K
- Bridgewater Associates LP−46.4K
- OLD NATIONAL BANCORP /IN/−4.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 254 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PBH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 10-K | May 14, 2026 | Mar 31, 2026 | - | |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PBH SEC filings: frequently asked questions
Which institutions hold PBH stock?
As of September 30, 2026, the largest Prestige Consumer Healthcare Inc. (PBH) holders among the 13F filers tracked by SignalX were BlackRock ($360.5 million), Vanguard Portfolio Management LLC ($128.9 million), Dimensional Fund Advisors ($121.5 million), State Street Corp ($101.4 million), Vanguard Capital Management LLC ($98.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PBH's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), Prestige Consumer Healthcare Inc. (PBH) reported revenue of $1.1 billion (down 4.3% from FY2025) and net income of $190.3 million. Diluted EPS was $3.91. The figures come from the XBRL data in the 10-K.
What did PBH report in its latest 8-K?
Prestige Consumer Healthcare Inc. (PBH) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Earnings announcement covers fiscal quarter and six months ended September 30, 2026.
What are the latest PBH SEC filings?
Prestige Consumer Healthcare Inc. (PBH) filed its latest 10-K annual report on May 14, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on August 5, 2026.
What is PBH's SEC CIK number?
Prestige Consumer Healthcare Inc. (PBH)'s SEC Central Index Key (CIK) is 1295947. EDGAR lists every PBH filing under that number.
Ask anything about PBH
The research agent reads PBH's filings, financials, insider trades and 13F holders, then answers with sources.